Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
Phase 2 N=21 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Disorder Related to Lung Transplantation · Bronchiolitis Obliterans · Decreased Immunologic Activity
Primary: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point — 2; 5 Participants — p=0.03
Phase 2 N=114 Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Ischemia-Reperfusion Injury · Lung Transplantation
Primary: PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours — 346.3; 337.9; 320.1; 307.3 ratio of PaO2/FiO2 — p=0.8541
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 3 N=169 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 2 N=23 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Constrictive Bronchiolitis · Bronchiolitis Obliterans · Graft vs Host Disease
Primary: Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS) — 9; 0 Participants
N/A N=207 Autologous Stem Cell Treatment for Chronic Lung Disease Study
COPD · Interstitial Lung Disease
Primary: Change in FEV1 From Baseline Among COPD Patients — 12.8 percentage of change in FEV1
N/A N=79 International EXPAND Lung Pivotal Trial
Lung Transplant
Primary: Number of Participants With Composite Endpoint of Patient Survival at Day-30 Post Transplant and Absence of Primary Graft Dysfunction (PGD) Grade 3 During the First 72…
Phase 3 N=62 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (L) From Baseline to Week 48 — -0.186; -0.090 liters — p=0.7310
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
N/A N=9 Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
Emphysema
Primary: Count of Patients With Grade 3 or Higher Adverse Events. — 3 Participants
Phase 2 N=25 Montelukast to Treat Bronchiolitis Obliterans
Bronchiolitis Obliterans · Chronic Graft Versus Host Disease · Leukotriene
Primary: Number of Participants With Stable or Improved Predicted Forced Expiratory Volume 1 (FEV-1) With Published Literature — 5; 7; 6; 1 Participants
Phase 3 N=535 RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
COPD (Chronic Obstructive Pulmonary Disease)
Primary: Proportion (Percentage) of Individuals Who Experience a 4 Unit Improvement in St. George's Respiratory Questionnaire (SGRQ) at 12 Weeks and do Not Meet Criteria for…
Phase 3 N=43 CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 4 N=40 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Hypotension · Kidney Injury
Primary: Development of Renal Injury — 0.8; 0.74 mg/dL — p=0.31
Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
N/A N=320 International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation
Lung Preservation
Primary: A Composite of Patient Survival at Day 30 Post Transplantation, and Absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction…
Phase 3 N=89 Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
N/A N=489 An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
COPD · Interstitial Lung Disease
Primary: Change in Quality of Life (QOL) From Baseline — 35.35; 27.96; 26.87 score on a scale
Phase 2 N=171 Imaging Regional Lung Defect Severity
COPD
Primary: Gas Trapping Measured During Washout of the Perfluorinated Gas Mixture. — 0.718; 0.541; 0.308; 0.451 percentage of total lung volume — p=<0.0001
Phase 2 N=32 Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
Lung Transplant Infection · Lower Respiratory Tract Infection
Primary: Lung Clearance Index 2% (LCI2%) — 10.68; 11.65; 10.09; 11.19 Index (change)
Phase 3 N=738 Long-term Oxygen Treatment Trial
Chronic Obstructive Pulmonary Disease
Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52
Phase 3 N=68 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
Lung Transplantation
Primary: Maximum Concentration (Cmax) of Mycophenolic Acid (MPA), Mycophenolic Acid Glucuronide (MPAG) and Acyl Glucuronide Metabolite of Mycophenolic Acid (AcMPAG) at Day 4…
Phase 2 N=27 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Lung Transplant Rejection · Antibody-mediated Rejection
Primary: Donor-specific HLA Antibodies, Re-transplantation, or Death — 0; 5; 3; 3 participants